Abstract Number: 1499 • ACR Convergence 2021
Imbalance Between T Follicular Cells and T Regulatory Cells Involved in High Fat-Diet Associated Lupus Development in MRL/lpr Mice
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease characterized by persistent inflammation and production of autoantibodies, which deposit within numerous tissues leading to…Abstract Number: 1637 • ACR Convergence 2021
Covid-19 Infection Among Pediatric Rheumatology Patients: A Single Center Experience
Background/Purpose: Infection with novel coronavirus (COVID-19) in children, unlike adults, is generally asymptomatic or causes mild disease although some may develop severe illness. In particular,…Abstract Number: 1740 • ACR Convergence 2021
Efficacy of Anifrolumab in Patients with SLE Previously Treated with Biologics: Post Hoc Analysis of Data from 2 Phase 3 Trials
Background/Purpose: In the phase 3 TULIP-1 and TULIP-2 trials, anifrolumab, a type I IFN receptor mAb, improved disease activity in patients with SLE.1,2 We investigated…Abstract Number: 1758 • ACR Convergence 2021
WITHDRAWN
Abstract Number: 1909 • ACR Convergence 2021
Impact of Antimalarial Adherence on Cardiovascular Mortality Among Patients with Newly Diagnosed Rheumatoid Arthritis and Systemic Lupus Erythematosus: A Population-based Study
Background/Purpose: Literature has shown poor adherence to antimalarial (AM) medications in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) patients, with the percentage of adherers…Abstract Number: 0164 • ACR Convergence 2021
Disrupted Executive Control Network Structural-Functional Integration Is Associated with Inferior Performance of Cognitive Switching Tasks in Patients with Systemic Lupus Erythematosus (SLE)
Background/Purpose: Cognitive flexibility, a process that enables goal-oriented cognitive switching between mental function modes, is central to executive function which is impaired in SLE patients.…Abstract Number: 0335 • ACR Convergence 2021
Performances of Different Classification Criteria for Systemic Lupus Erythematosus in a Single Center Cohort from Turkey
Background/Purpose: Recently developed EULAR/ACR classification criteria for systemic lupus erythematosus (SLE) has important differences compared to the 2012 Systemic Lupus International Collaborating Clinics (SLICC) SLE…Abstract Number: 0354 • ACR Convergence 2021
A Cross-Sectional Study of Rheumatoid Arthritis Diagnoses in Patients with Systemic Lupus Erythematosus
Background/Purpose: Features of autoimmune conditions may coexist in individual patients, which may represent an overlapping single disease with features of both (i.e., ‘rhupus’), or the…Abstract Number: 0537 • ACR Convergence 2021
The Clinical, Oral Small Molecule IRAK4 Inhibitor, GS-5718, Improves Survival and Reduces Disease Pathologies by Modulating Multiple Inflammatory Endpoints in the Murine NZB/W Model of Spontaneous Lupus
Background/Purpose: Lupus is a heterogenous autoimmune disease characterized by loss of immune tolerance, production of nucleic acid:autoantibody immune complexes, immune cell hyperactivation, and increased proinflammatory…Abstract Number: 0628 • ACR Convergence 2021
Higher Quality of Care for Patients with Systemic Lupus Erythematosus in a Subspecialty Lupus Clinic: A Multi-Setting Cross-Sectional Study
Background/Purpose: Healthcare quality for systemic lupus erythematosus (SLE) is a modifiable target for improving patient outcomes. Disease-specific subspecialty lupus clinics may offer experienced healthcare professionals,…Abstract Number: 0859 • ACR Convergence 2021
Evaluation of the Montreal Cognitive Assessment as a Screening Tool for Cognitive Dysfunction in Systemic Lupus Erythematosus
Background/Purpose: Cognitive dysfunction (CD) affects approximately 40% of SLE patients (1), impacting on employment, daily function, and quality of life (2)(3). Diagnostic neuropsychological testing is…Abstract Number: 0876 • ACR Convergence 2021
Antibody Response in Patients with Systemic Lupus Erythematosus After a Two-dose Regimen with SARS-CoV-2 Vaccines (Preliminary Results)
Background/Purpose: Patients with Systemic Lupus Erythematosus (SLE) often receive immunosuppressive treatment for many years, resulting in higher risk of infections, including COVID-19, and infections may…Abstract Number: 0894 • ACR Convergence 2021
Help-seeking Behaviors and Treatment Preferences for Sleep Problems Among Persons with Lupus
Background/Purpose: Sleep disturbances, including difficulty initiating sleep, maintaining sleep, and/or early morning awakenings are prevalent among persons with lupus and have been shown to contribute…Abstract Number: 1042 • ACR Convergence 2021
Multimorbidity Prevalence in Systemic Lupus Erythematosus: A Population-Based Study
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have a 3-fold increase in all-cause mortality, compared to the general population. Young patients with SLE are 40…Abstract Number: 1257 • ACR Convergence 2021
Improvements in Abnormal Laboratory Tests Are Associated with Clinical Outcomes in Patients with Active Systemic Lupus Erythematosus
Background/Purpose: Laboratory tests are routine in the management of SLE. In clinical trial endpoints, data from laboratory tests contribute to responder status, but this is…
- « Previous Page
- 1
- …
- 57
- 58
- 59
- 60
- 61
- …
- 119
- Next Page »